Literature DB >> 10207105

Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression.

L Soon1, L Flechner, J S Gutkind, L H Wang, R Baserga, J H Pierce, W Li.   

Abstract

In the present study, we investigated the potential role of insulin-like growth factor I (IGF-I) receptor (IGF-IR) in cell proliferation by overexpressing it in 32D myeloid progenitor cells. The overexpression of IGF-IR caused the transfectants to proliferate in response to IGF-I in the absence of insulin receptor substrate (IRS) expression. The activation of overexpressed wild-type IGF-IR, but not that of an ATP-binding mutant of IGF-IR, resulted in the increased tyrosine phosphorylation of several intracellular proteins, including SHC, Src homology 2-containing inositol-5-phosphatase, protein kinase C-delta, and Erk2. Grb2 association with SHC and mitogen-activated protein kinase (MAPK) activity was also enhanced in response to IGF-I stimulation. Interestingly, the stimulation of the IGF-IR transfectants with interleukin 4 (IL-4) also resulted in strong mitogenesis independent of IRS expression. Moreover, IGF-I and/or IL-4 induced long-term cell growth of the IGF-IR transfectants. IL-4 was able to synergize with IGF-I for DNA synthesis, even in the parental 32D cells and a pro-B-cell line, Baf3, indicating the physiological importance of the two growth factors in hematopoietic cell proliferation. IL-4 stimulation of the IGF-IR transfectants resulted in enhanced tyrosine phosphorylation of SHC, Erk2, and signal transducer and activator of transcription 6 (STAT6) proteins. Both IL-4 and IGF-I were able to induce c-myc early response gene expression, and this expression was maximal in the presence of both factors. Finally, we demonstrated that a MAPK kinase inhibitor was able to suppress mitogenesis of the IGF-IR transfectants in response to IGF-I and/or IL-4. Together, our results suggest that IL-4 synergizes with IGF-I for hematopoietic cell proliferation, likely through cross talk between SHC/Grb2/MAPK and STAT6 pathways and through c-myc gene up-regulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10207105      PMCID: PMC84225          DOI: 10.1128/MCB.19.5.3816

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  51 in total

1.  The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase.

Authors:  J E Damen; L Liu; P Rosten; R K Humphries; A B Jefferson; P W Majerus; G Krystal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

2.  Insulin-like growth factor-I augments erythropoietin-induced proliferation through enhanced tyrosine phosphorylation of STAT5.

Authors:  Y Okajima; I Matsumura; T Nishiura; K Hashimoto; H Yoshida; J Ishikawa; H Wakao; A Yoshimura; Y Kanakura; Y Tomiyama; Y Matsuzawa
Journal:  J Biol Chem       Date:  1998-09-04       Impact factor: 5.157

3.  Interleukin 4 signals through two related pathways.

Authors:  A Pernis; B Witthuhn; A D Keegan; K Nelms; E Garfein; J N Ihle; W E Paul; J H Pierce; P Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

Review 4.  Signal transduction through the IL-4 and insulin receptor families.

Authors:  L M Wang; A Keegan; M Frankel; W E Paul; J H Pierce
Journal:  Stem Cells       Date:  1995-07       Impact factor: 6.277

5.  Distinct modes of interaction of SHC and insulin receptor substrate-1 with the insulin receptor NPEY region via non-SH2 domains.

Authors:  W He; T J O'Neill; T A Gustafson
Journal:  J Biol Chem       Date:  1995-10-06       Impact factor: 5.157

Review 6.  Interleukin 4 receptor: signaling mechanisms.

Authors:  A D Keegan; K Nelms; L M Wang; J H Pierce; W E Paul
Journal:  Immunol Today       Date:  1994-09

7.  Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor.

Authors:  Y Jiang; J L Chan; C S Zong; L H Wang
Journal:  J Biol Chem       Date:  1996-01-05       Impact factor: 5.157

8.  Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain.

Authors:  T A Gustafson; W He; A Craparo; C D Schaub; T J O'Neill
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

9.  Mutant IGF-I receptors as dominant negatives for growth and transformation.

Authors:  J L Burgaud; M Resnicoff; R Baserga
Journal:  Biochem Biophys Res Commun       Date:  1995-09-14       Impact factor: 3.575

10.  Role of IRS-2 in insulin and cytokine signalling.

Authors:  X J Sun; L M Wang; Y Zhang; L Yenush; M G Myers; E Glasheen; W S Lane; J H Pierce; M F White
Journal:  Nature       Date:  1995-09-14       Impact factor: 49.962

View more
  16 in total

1.  Regulation of Id gene expression by type I insulin-like growth factor: roles of Stat3 and the tyrosine 950 residue of the receptor.

Authors:  M Prisco; F Peruzzi; B Belletti; R Baserga
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

2.  Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells.

Authors:  Angelina Felici; Alessio Giubellino; Donald P Bottaro
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

3.  Insulin-like Growth Factor 1 Supports a Pulmonary Niche that Promotes Type 3 Innate Lymphoid Cell Development in Newborn Lungs.

Authors:  Katherine Oherle; Elizabeth Acker; Madeline Bonfield; Timothy Wang; Jerilyn Gray; Ian Lang; James Bridges; Ian Lewkowich; Yan Xu; Shawn Ahlfeld; William Zacharias; Theresa Alenghat; Hitesh Deshmukh
Journal:  Immunity       Date:  2020-02-18       Impact factor: 31.745

4.  Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation.

Authors:  Dunhua Zhou; Divino Deoliveira; Yubin Kang; Seung S Choi; Zhiguo Li; Nelson J Chao; Benny J Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-09-25       Impact factor: 7.038

Review 5.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

6.  Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R.

Authors:  Ellen Weisberg; Atsushi Nonami; Zhao Chen; Erik Nelson; Yongfei Chen; Feiyang Liu; HaeYeon Cho; Jianming Zhang; Martin Sattler; Constantine Mitsiades; Kwok-Kin Wong; Qingsong Liu; Nathanael S Gray; James D Griffin
Journal:  Clin Cancer Res       Date:  2014-09-03       Impact factor: 12.531

Review 7.  IGF-I receptor signalling in transformation and differentiation.

Authors:  B Valentinis; R Baserga
Journal:  Mol Pathol       Date:  2001-06

8.  IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma.

Authors:  Tohru Hosoyama; Mohammed Imran Aslam; Jinu Abraham; Suresh I Prajapati; Koichi Nishijo; Joel E Michalek; Lee Ann Zarzabal; Laura D Nelon; Denis C Guttridge; Brian P Rubin; Charles Keller
Journal:  Clin Cancer Res       Date:  2011-05-01       Impact factor: 12.531

Review 9.  The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.

Authors:  Morteza Motallebnezhad; Leili Aghebati-Maleki; Farhad Jadidi-Niaragh; Hamid Nickho; Hosein Samadi-Kafil; Karim Shamsasenjan; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2016-07-21

Review 10.  Pleiotropic Effect of Hormone Insulin-Like Growth Factor-I in Immune Response and Pathogenesis in Leishmaniases.

Authors:  Luiza C Reis; Eduardo Milton Ramos-Sanchez; Fernanda N Araujo; Ariane F Leal; Christiane Y Ozaki; Orlando R Sevillano; Bernardina A Uscata; Hiro Goto
Journal:  J Immunol Res       Date:  2021-05-04       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.